Tumble out of bed and stumble to the kitchen, pour myself a cup of ambition, and yawn and stretch and try to come to life. Jump in the shower, and the blood starts pumpin’, out on the streets, the traffic starts jumpin’, for folks like me on the job … STAT reporter Andrew Joseph here filling in for Ed, offering up some Dolly Parton along with industry headlines to cure your candy hangovers.
Pfizer’s maternal vaccine against the respiratory syncytial virus reduced the rate of severe illness in newborns by 81.8%, the company said Tuesday, meeting the goal of a pivotal study, STAT tells us. The company said that it plans to file the data on the vaccine with regulators by the end of the year and that it expects an eight-month review. RSV is a common cause of illness and infection in infants. By giving the vaccine during pregnancy, researchers hope antibodies generated by mothers would be transferred to their babies.
More news from Pfizer: The company raised its sales forecast for the year for its Covid-19 vaccine by $2 billion to $34 billion on Tuesday, as higher prices have managed to offset slowing jab demand outside the U.S., the Financial Times writes. The drugmaker said strong sales of its bivalent booster, which targets the Omicron variant’s dominant strain, and some of its other drugs helped offset damage from a strong dollar. The company maintained its full-year forecast of $22 billion for sales of its antiviral pill Paxlovid, as it posted third quarter results that beat analysts’ expectations and soothed concerns about weaker demand for Covid products.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect